$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the treatment course and cycle of Asnib/Asiminib (Sinbel) in the treatment of chronic myelogenous leukemia
2026-02-01 22:25:32
Check Details
The dosage and individualized adjustment plan of ritexitinib (Lefenox)
2026-02-01 22:25:32
Check Details
Will sparsentan cause liver and kidney toxicity and safety analysis
2026-02-01 22:25:32
Check Details
A comprehensive analysis of the functions, efficacy and indications of Ixazomib (Enleri)
2026-02-01 22:25:32
Check Details
Analysis of the medication regimen of rubitin/rubicatin (Zanbiga) combined with irinotecan
2026-02-01 22:25:32
Check Details
A detailed introduction and explanation of which diseases and indications Anagrelide mainly treats
2026-02-01 22:25:32
Check Details
What diseases is Apalutamide (Ansenko) mainly used to treat and its clinical scope of application?
2026-02-01 22:25:32
Check Details
Is there any generic drug of Elacetrant on the market and analysis of the market prospects of generic drugs
2026-02-01 22:25:32
Check Details
Can F/TAF be taken alone? Still need professional advice on combined medication?
2026-02-01 22:25:32
Check Details
Things to note when taking Febuxostat (Febuxostat) and description of contraindications and risks
2026-02-01 22:25:32
Check Details
How long does it take to see significant efficacy and evaluation of furmonertinib?
2026-02-01 22:25:32
Check Details
The formal purchasing channels for ensifentrine-Ohtuvayre and suggestions on preventing the risks of counterfeit drugs
2026-02-01 22:25:32
Check Details
1
2
...
2190
2191
2192
2193
2194
2195
2196
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib Medication Management Guide for Special Populations
2
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
3
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
4
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
5
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
6
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
7
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
8
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
9
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
10
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
11
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
12
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management